Gilbert Technologies

Gilbert Technologies is a Dutch company that designs and develops medical devices to improve health care, patient care and that offers a better quality of life through innovative and disruptive sustainable health technologies. The technology is applied in novel medical inhalation devices with market-leading lung deposition characteristics for pulmonary medicine administration for Cystic Fibrosis (CF), Asthma, Oncology (Lung cancer), Pulmonary Arterial Hypertension, as well as Non-CF Bronchiectasis, Chronic Obstructive Pulmonary Disease (COPD), Idiopathic Pulmonary Fibrosis, Transplantation, Pain management, Vaccination and other indications.

NEWS

June 7, 2023

Gilbert Technologies Completes Series A Investment Round

Dutch MedTech Company Gilbert Technologies Raises €7 Million Series A to Redefine Treatment for Lung Patients.

Eindhoven, The Netherlands, June 7 2023 – Gilbert Technologies, today announced the completion of its €7 million Seed – and Series A investment round. The investment rounds are led by Dutch deeptech investor DeeptechXL and joined by existing shareholders NanoCorp and Delft Enterprises.

Click here for the full press release.

Inhaler device

An innovative monodisperse aerosol technology where droplet size can vary in such a way that medication can be accurately and locally targeted in the lungs.

What we believe

We turn complexity into simplicity. We expand access to healthcare and offer better convenience, comfort and mobility to patients and enhance patient adherence.

Sustainability

Through our core business, we stimulate socially responsible initiatives in health care by utilizing innovative development opportunities.

Our strategy

Our strategy is to use science-based innovation to deliver better patient outcomes. We aim to lead in certain growing areas of healthcare.

“Gilbert Technologies’ EHDA technology has the potential to offer unique benefits to patients for aerosolization and medication targeting of more complex and advanced molecular entities for respiratory diseases and for pulmonary administration of molecules for other indication areas.”

Prof. P.N.R. (Richard) Dekhuijzen

Professor of Pulmonology, University Lung Center Nijmegen, Expert Board ADMIT

“Gilbert Technologies’ EHDA technology is one of the most promising innovations in device inhalation technology, offering substantial advantages to patients compared to current commercial available inhalation technology solutions.”

Wim Vos MSc, PhD

Chief Executive Officer RADIOMICS

Therapeutic applications

• CF (Cystic Fibrosis)
• Asthma
• Oncology (Lung Cancer)
• Pulmonary Arterial Hypertension
• Other lung indications
• Systemic indications

Our technology

• Pulmonary drug delivery
• Pulmonary administration route
• Basic principle of EHDA

Our Partners

• TU Delft
• NHL University of Applied Sciences
• University Medical Center Utrecht
• Fluidda

Read more...

Contact

Gilbert Technologies B.V.
High Tech Campus 27
5656 AE Eindhoven – NL

Read more...

Terms of use | Company | What we believe | Strategy | Investors

^{Gilbert Technologies 2020}